Geron (GERN) Return on Capital Employed (2011 - 2026)
Geron's (GERN) quarterly Return on Capital Employed came in at 10.8% in Q1 2026, up 1527.0% year-on-year from 0.66% in Q1 2025, and up 27.95% quarter-over-quarter from 14.99% in Q4 2025.
Geron (GERN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Geron has disclosed Return on Capital Employed across 16 years of filings, most recently posting 10.8% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 10.8%, up 1527.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 10.8% (up 1527.0% YoY), and the FY2025 annual result was 14.57%, up 2826.0% from the prior year.
- Return on Capital Employed came in at 10.8% for Q1 2026 at Geron, up from 14.99% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 10.8% in Q1 2026 to a low of 102.71% in Q4 2022.
- The 5-year median for Return on Capital Employed is 56.85% (2023), against an average of 51.04%.
- Across the five-year window, Return on Capital Employed tumbled 4009 bps in 2022 and surged 5393 bps in 2025, its largest moves.
- Geron's Return on Capital Employed stood at 102.71% in 2022, then surged by 36 bps to 65.64% in 2023, then surged by 39 bps to 40.3% in 2024, then surged by 63 bps to 14.99% in 2025, then advanced by 28 bps to 10.8% in 2026.
- The last three Return on Capital Employed figures came in at 10.8% (Q1 2026), 14.99% (Q4 2025), and 13.32% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Geron | 729,618.77 | 729,618.77 | - | -10.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.80% |
| Dec 31, 2025 | -14.99% |
| Sep 30, 2025 | -13.32% |
| Jun 30, 2025 | -15.66% |
| Mar 31, 2025 | -26.07% |
| Dec 31, 2024 | -40.30% |
| Sep 30, 2024 | -67.25% |
| Jun 30, 2024 | -62.77% |
| Mar 31, 2024 | -66.68% |
| Dec 31, 2023 | -65.64% |
| Sep 30, 2023 | -55.92% |
| Jun 30, 2023 | -50.05% |
| Mar 31, 2023 | -56.85% |
| Dec 31, 2022 | -102.71% |
| Sep 30, 2022 | -83.62% |
| Jun 30, 2022 | -66.10% |
| Mar 31, 2022 | -68.97% |
| Dec 31, 2021 | -62.62% |
| Sep 30, 2021 | -52.57% |
| Jun 30, 2021 | -46.08% |